Skip to main content
. 2022 May 9;10(5):741. doi: 10.3390/vaccines10050741

Figure 5.

Figure 5

(A) Comparison of total anti-SARS-CoV-2 antibody levels in groups of women and men with and without a history of COVID-19. The data are presented as median (minimum-maximum). (B) Comparison of total anti-SARS-CoV-2 antibody levels in groups of patients under and over the age of 50 with and without a history of COVID-19. The data are presented as median (minimum-maximum). (C) Comparison of total anti-SARS-CoV-2 antibody levels in groups of patients with and without coexisting diseases with and without a history of COVID-19. The data are presented as median (minimum-maximum). (D) Comparison of total anti-SARS-CoV-2 antibody levels in groups of medical and non-medical workers with and without a history of COVID-19. The data are presented as median (minimum-maximum). (E) Comparison of total anti-SARS-CoV-2 antibody levels between group of patients with normal and increased BMI with and without a history of COVID-19. The data are presented as median (minimum–maximum).